Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

This study tests an experimental cell therapy (FT536, a type of NK cell therapy) delivered directly into the abdomen in patients with recurrent ovarian, fallopian tube, or primary peritoneal cancer — cancers that keep coming back after prior treatments. **You may be eligible if...** - You have recurrent epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer - You have previously received bevacizumab as part of your treatment - If your tumor has a BRCA mutation, you have previously received a PARP inhibitor - You are willing to have an intraperitoneal catheter (a tube in your abdomen) placed for the treatment - Your organ function is adequate **You may NOT be eligible if...** - You are pregnant, breastfeeding, or planning pregnancy in the next 6 months - You are unable to have the catheter placed safely - You are unwilling to participate in the required long-term follow-up study (up to 15 years) Talk to your doctor to see if this trial is right for you.